An optical coherence tomography study of two new generation stents with biodegradable polymer carrier, eluting paclitaxel vs. biolimus-A9

作者：Davlouros Periklis A^*; Mavronasiou Eleni; Xanthopoulou Ioanna; Karantalis Vasileios; Tsigkas Grigorios; Hahalis George; Alexopoulos Dimitrios

来源：International Journal of Cardiology, 2012, 157(3): 341-346.

DOI：10.1016/j.ijcard.2010.12.072

• OCT
• Paclitaxel
• Biolimus-A9
• Neointimal coverage
• Malapposition

Background: Tissue coverage and strut apposition of drug eluting stents (DES), which can be assessed with optical coherence tomography (OCT), may be associated with late stent thrombosis (LST). %26lt;br%26gt;Methods: Prospective observational angiographic and OCT follow-up at 6 months post-implantation of a biolimus-A9 eluting stent (BES) vs. a paclitaxel eluting stent (PES), with biodegradable polymer carriers. The primary outcome was the percent difference of uncovered struts between BESs and PESs. %26lt;br%26gt;Results: A maximum likelihood model was used for analysis, to account for data clustering. Sixteen patients were treated with BES (28 lesions/4530 struts) and 16 with PES (23 lesions/4450 struts). Overall, BESs compared to PESs had more uncovered [0.41% vs. 0.21%, difference estimate (DE) 0.2 (95% CI, 0.06-0.34), p=0.006], malapposed [0.18% vs. 0.04%, DE 0.14 (95% CI 0.05-0.23), p=0.003], uncovered and malapposed [0.08% vs. 0.026%, DE 0.057 (95% CI 0.015-0.1), p=0.01] and protruding struts [0.23% vs. 0.04%, DE 0.185 (95% CI 0.1-0.27), p%26lt;0.001], and significantly lower neointimal thickness (59.3 +/- 28.2 mu m vs. 201.7 +/- 97.5, p%26lt;0.001). None of the BESs was totally covered with neointima, in contrast to 5 (21.7%) PESs (p=0.01). Thrombus was detected in 1 (3.6%) BES and 5 (21.7%) PESs (p=0.05); however, no patient experienced clinical stent thrombosis. %26lt;br%26gt;Conclusion: Between two stents with biodegradable polymer, OCT demonstrated that BESs had more uncovered and malapposed struts compared to PESs at 6 months. This difference might be partly attributed to the more potent antiproliferative properties of biolimus-A9; however, its impact on clinical outcome and on the risk of LST is yet to be determined.

• 出版日期2012-6-14